Potent and sustained inhibition of HIF-1α and downstream genes by a polyethyleneglycol-SN38 conjugate, EZN-2208, results in anti-angiogenic effects

Angiogenesis

Volumn 14, Issue 3, 2011, Pages 245-253

  Sapra, Puja ^a,d   Kraft, Patricia ^a   Pastorino, Fabio ^b   Ribatti, Domenico ^c   Dumble, Melissa ^a   Mehlig, Mary ^a   Wang, Maoliang ^a   Ponzoni, Mirco ^b   Greenberger, Lee M ^a   Horak, Ivan D ^a  

^a Enzon Pharmaceuticals   (United States)

^b G GASLINI INSTITUTE   (Italy)

^c UNIVERSITY OF BARI   (Italy)

^d PFIZER INC   (United States)

Author keywords

Angiogenesis; CPT 11 (Camptosar); HIF 1 ; Pegylation; SN38

Indexed keywords

ANGIOGENESIS INHIBITOR; EZN 2208; GLUCOSE TRANSPORTER 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IRINOTECAN; LUCIFERASE; MESSENGER RNA; PEGYLATED 7 ETHYL 10 HYDROXYCAMPTOTHECIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG CONJUGATION; DRUG EFFICACY; DRUG POTENCY; GENE EXPRESSION REGULATION; GLIOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; REPORTER GENE; TUMOR XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CELL LINE, TUMOR; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE; MICE, NUDE; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; POLYETHYLENE GLYCOLS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS;

EID: 80052691602     PISSN: 09696970     EISSN: 15737209     Source Type: Journal    
DOI: 10.1007/s10456-011-9209-1     Document Type: Article

References (24)

1. GL Semenza 2000 Hypoxia, clonal selection, and the role of HIF-1 in tumor progression Crit Rev Biochem Mol Biol 35 71 103 10821478 10.1080/ 10409230091169186 1:CAS:528:DC%2BD3cXjsFChsLc%3D (Pubitemid 30253678)
2. GL Semenza 2003 Targeting HIF-1 for cancer therapy Nat Rev Cancer 3 721 732 13130303 10.1038/nrc1187 1:CAS:528:DC%2BD3sXotFCiu70%3D (Pubitemid 37328811)
3. H Zhong AM De Marzo E Laughner, et al. 1999 Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases Cancer Res 59 5830 5835 10582706 1:CAS:528:DyaK1MXnslygsr0%3D
4. Rahman R, Smith S, Rahman C, et al. (2010) Antiangiogenic therapy and mechanisms of tumor resistance in malignant glioma. J Oncol 251231 (Epub 2010 Apr 11)
5. Takano S, Yamashita T, Ohneda O (2010) Molecular therapeutic targets for glioma angiogenesis. Published online J Oncology 351908 (Epub 2010 Apr 18)
6. Nussenbaum F, Herman IM (2010) Tumor angiogenesis: insights and innovations. J Oncol 132641 (Epub 2010 Apr 26)
7. N Ferrara HP Gerber J LeCouter 2003 The biology of VEGF and its receptors Nat Med 9 669 676 12778165 10.1038/nm0603-669 1:CAS:528:DC%2BD3sXktFOnur4%3D (Pubitemid 36749215)
8. GL Semenza 2007 Evaluation of HIF-1 inhibitors as anticancer agents Drug Discov Today 12 853 859 17933687 10.1016/j.drudis.2007.08.006 1:CAS:528:DC%2BD2sXhtFKit77O (Pubitemid 47554628)
9. Poon E, Harris AL, Ashcroft M (2009) Targeting the hypoxia-inducible factor (HIF) pathway in cancer. Expert Rev Mol Med 11:e26
10. A Rapisarda B Yranchimeg DA Scudiero, et al. 2002 Identification of small molecule inhibitors of hypoxia-inducible factor-1 transcriptional activation pathway Cancer Res 62 4316 4324 12154035 1:CAS:528:DC%2BD38XlvFeltbc%3D (Pubitemid 34827288)
11. A Rapisarda J Zalek M Hollingshead, et al. 2004 Schedule-dependent inhibition of hypoxia-inducible factor-1 protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts Cancer Res 64 6845 6848 15466170 10.1158/0008-5472.CAN-04-2116 1:CAS:528:DC%2BD2cXotFalsr8%3D (Pubitemid 39330988)
12. A Rapisarda B Uranchimeg O Sordet, et al. 2004 Topoisomerase I-mediated inhibition of hypoxia-inducible factor-1: mechanism and therapeutic implications Cancer Res 64 1475 1482 14983893 10.1158/0008-5472.CAN-03-3139 1:CAS:528:DC%2BD2cXhtleitL4%3D (Pubitemid 38235619)
13. H Zhao B Rubio P Sapra, et al. 2008 Novel prodrugs of SN38 using multiarm poly(ethylene glycol) linkers Bioconjugate Chem 19 849 859 10.1021/bc700333s 1:CAS:528:DC%2BD1cXjvFOltbc%3D (Pubitemid 351614540)
14. P Sapra H Zhao M Mehlig, et al. 2008 Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a Camptothecin-11 refractory model Clin Cancer Res 14 1888 1896 18347192 10.1158/1078-0432.CCR-07-4456 1:CAS:528:DC%2BD1cXjtleis7s%3D (Pubitemid 351469476)
15. P Sapra P Kraft M Mehlig, et al. 2009 Marked therapeutic efficacy of a novel polyethylene glycol-SN38 conjugate, EZN-2008, in xenograft models of non-Hodgkin's lymphoma Hematologica 10 1456 1459 10.3324/haematol.2009.008276
16. Pastorino F, Loi M, Sapra P, et al. (2010) Tumor regression and curability of preclinical neuroblastoma models by PEGylated SN38 (EZN-2208), a novel topoisomerase I inhibitor. Clin Cancer Res 16:4809-4821
17. D Ribatti B Nico A Vacca, et al. 2006 The gelatin sponge-chorioallantoic membrane assay Nat Protoc 1 85 91 17406216 10.1038/nprot.2006.13 1:CAS:528:DC%2BD28XhtFOitb3N
18. F Pastorino DD Paolo F Piccardi, et al. 2008 Enhanced antitumor efficacy of clinical-grade vasculature-targeted liposomal doxorubicin Clin Cancer Res 14 7320 7329 19010847 10.1158/1078-0432.CCR-08-0804 1:CAS:528:DC%2BD1cXhtlylur7F
19. F Pastorino C Brignole D Di Paolo, et al. 2006 Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy Cancer Res 66 10073 10082 17047071 10.1158/0008-5472.CAN-06-2117 1:CAS:528:DC%2BD28XhtVyiur7K (Pubitemid 44672061)
20. A Passanti RM Taylor R Pili, et al. 1992 A simple, quantitative method for assessing angiogenesis and antiangiogenesis using reconstituted basement membrane, heparin, and fibroblast growth factor Lab Invest 67 519 528
21. R Kumar VB Knick SK Rudolph, et al. 2007 Pharmacokinetic-pharmacodynamic relationship from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity Mol Cancer Thera 6 2012 2021 10.1158/1535-7163.MCT-07-0193 1:CAS:528:DC%2BD2sXnsV2jsrk%3D (Pubitemid 47052491)
22. G Melillo 2007 Hypoxia-inducible factor 1 inhibitors Methods Enzymol 435 385 402 17998065 10.1016/S0076-6879(07)35020-9 1:CAS:528:DC%2BD1cXhtVOjuro%3D
23. RHJ Mathijssen RJ van Alphen J Verweij, et al. 2001 Clinical pharmacokinetics and metabolism of irinotecan (CTP-11) Clin Cancer Res 7 2182 2194 11489791 1:CAS:528:DC%2BD3MXmsVOmsbg%3D (Pubitemid 32751614)
24. EB Rankin AJ Giaccia 2008 The role of hypoxia-inducible factors in tumorigenesis Cell Death Differ 15 678 685 18259193 10.1038/cdd.2008.21 1:CAS:528:DC%2BD1cXjtl2jur8%3D (Pubitemid 351405072)